Publications by authors named "Kenneth E Hung"

Claim this Profile
A
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
Silvio Danese, Jessica R Allegretti, Stefan Schreiber, Laurent Peyrin-Biroulet, Vipul Jairath, Kenneth E Hung

Lancet Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Japanese Phase 1 Study for Global Development of Anti-TL1A Antibody PF-06480605: A Randomized, Placebo-Controlled, Single-Ascending Dose Study.
Kei Fukuhara, Srividya Neelakantan, Kenichi Furihata, Hirotoshi Yuasa, Nanzhi Shi, Kenneth E Hung

Clin Transl Sci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
Mina Hassan-Zahraee, Zhan Ye, Li Xi, Elizabeth Dushin, Julie Lee, Kenneth E Hung

J Crohns Colitis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
William J Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, Jacek Romatowski, Engin Altintas, Kenneth E Hung

Clin Gastroenterol Hepatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
Mina Hassan-Zahraee, Zhan Ye, Li Xi, Mary Lynn Baniecki, Xingpeng Li, Kenneth E Hung

Inflamm Bowel Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.
Silvio Danese, Maria Klopocka, Ellen J Scherl, Jacek Romatowski, Jessica R Allegretti, Kenneth E Hung

Clin Gastroenterol Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Christopher Banfield, Dan Rudin, Indranil Bhattacharya, Kosalaram Goteti, Gang Li, Kenneth E Hung

Br J Clin Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKM2 is not required for colon cancer initiated by APC loss.
Allison N Lau, William J Israelsen, Jatin Roper, Mark J Sinnamon, Larissa Georgeon, Kenneth E Hung

Cancer Metab· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Peter J Belmont, Ping Jiang, Trevor D McKee, Tao Xie, Jason Isaacson, Kenneth E Hung

Sci Signal· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture.
Xingnan Li, Lincoln Nadauld, Akifumi Ootani, David C Corney, Reetesh K Pai, Kenneth E Hung

Nat Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Jatin Roper, Mark J Sinnamon, Erin M Coffee, Peter Belmont, Lily Keung, Kenneth E Hung

Cancer Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras.
Alexander J Byun, Kenneth E Hung, James C Fleet, Roderick T Bronson, Joel B Mason

Cancer Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.
Peter J Belmont, Eva Budinska, Ping Jiang, Mark J Sinnamon, Erin Coffee, Kenneth E Hung

Dis Model Mech· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development.
Jatin Roper, Eric S Martin, Kenneth E Hung

Curr Protoc Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Anthony C Faber, Erin M Coffee, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Kenneth E Hung

Cancer Discov· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo optical molecular imaging of matrix metalloproteinase activity following celecoxib therapy for colorectal cancer.
Rahul A Sheth, Alexandra Kunin, Lars Stangenberg, Mark Sinnamon, Kenneth E Hung

Mol Imaging· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.
Eric S Martin, Peter J Belmont, Mark J Sinnamon, Larissa Georgeon Richard, Jing Yuan, Kenneth E Hung

Clin Cancer Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
Erin M Coffee, Anthony C Faber, Jatin Roper, Mark J Sinnamon, Gautam Goel, Kenneth E Hung

Clin Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, Anthony C Faber, Hiromichi Ebi, Kenneth E Hung

Cancer Cell· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Sergei I Grivennikov, Kepeng Wang, Daniel Mucida, C Andrew Stewart, Bernd Schnabl, Kenneth E Hung

Nature· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development.
Jatin Roper, Kenneth E Hung

Trends Pharmacol Sci· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Ryan B Corcoran, Hiromichi Ebi, Alexa B Turke, Erin M Coffee, Michiya Nishino, Kenneth E Hung

Cancer Discov· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.
Jatin Roper, Michael P Richardson, Wei Vivian Wang, Larissa Georgeon Richard, Wei Chen, Kenneth E Hung

PLoS One· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia.
Andrew T Chan, Yoshifumi Baba, Kaori Shima, Katsuhiko Nosho, Daniel C Chung, Kenneth E Hung

Cancer Epidemiol Biomarkers Prev· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo wide-area cellular imaging by side-view endomicroscopy.
Pilhan Kim, Euiheon Chung, Hiroshi Yamashita, Kenneth E Hung, Atsushi Mizoguchi

Nat Methods· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis